Inhibiting tumor growth by targeting tumor vasculature with galectin-1 antagonist anginex conjugated to the cytotoxic acylfulvene, 6- hydroxylpropylacylfulvene

Bioconjugate Chemistry

Volumn 21, Issue 1, 2010, Pages 20-27

  Dings, Ruud P M ^a   Van Laar, Emily S ^b   Loren, Melissa ^a   Webber, Jeremy ^b   Zhang, Yan ^a   Waters, Stephen J ^b   MacDonald, John R ^b   Mayo, Kevin H ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b GUILFORD PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXICITY; ENDOTHELIAL CELLS; TUMORS;

CYTOTOXIC; CYTOTOXIC AGENTS; ENDOTHELIAL-CELLS; GALECTIN-1; OVARIAN CANCERS; TARGETED DELIVERY; THERAPEUTIC DRUGS; TUMOR GROWTH; TUMOR VASCULATURE; TUMOR VESSELS;

DISEASES;

6 HYDROXYPROPYLACYLFULVENE; ANGINEX; CARBOPLATIN; CYTOTOXIC AGENT; GALECTIN 1; IROFULVEN; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CELL ADHESION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG CONJUGATION; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; MOUSE; NONHUMAN; OVARY CANCER; OVARY CARCINOMA; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VASCULARIZATION; WEIGHT GAIN;

MUS;

EID: 74949118349     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc900287y     Document Type: Article

References (30)

1. Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., Ferrara, N., Fyfe, G., Rogers, B., Ross, R., and Kabbinavar, F. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335-42.
2. Teicher, B. A., Sotomayor, E. A., and Huang, Z. D. (1992) Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res. 52, 6702-4.
3. Dings, R. P., Yokoyama, Y., Ramakrishnan, S., Griffioen, A. W., and Mayo, K. H. (2003) The designed angiostatic peptide anginex synergistically improves chemotherapy and antiangiogenesis therapy with Angiostatin. Cancer Res. 63, 382-385.
4. Griffin, R. J., Molema, G., and Dings, R. P. (2006) Angiogenesis treatment, new concepts on the horizon. Angiogenesis 9, 67-72.
5. Griffioen, A. W., and Molema, G. (2000) Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol. Rev. 52, 237-68.
6. Arap, W., Pasqualini, R., and Ruoslahti, E. (1998) Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279, 377-80.
7. Mulder, W. J., Strijkers, G. J., Habets, J. W., Bleeker, E. J., van der Schaft, D. W., Storm, G., Koning, G. A., Griffioen, A. W., and Nicolay, K. (2005) MR molecular imaging and fluorescence microscopy for identification of activated tumor endothelium using a bimodal lipidic nanoparticle. Faseb J. 19, 2008-10.
8. Griffioen, A. W., van der Schaft, D. W., Barendsz-Janson, A. F., Cox, A., Struijker Boudier, H. A., Hillen, H. F., and Mayo, K. H. (2001) Anginex, a designed peptide that inhibits angiogenesis. Biochem. J. 354, 233-42.
9. Dings, R. P., and Mayo, K. H. (2007) A journey in structure-based drug discovery: from designed peptides to protein surface topomimetics as antibiotic and antiangiogenic agents. Acc. Chem. Res. 40, 1057-65.
10. Thijssen, V. L., Postel, R., Brandwijk, R. J., Dings, R. P., Nesmelova, I., Satijn, S., Verhofstad, N., Nakabeppu, Y., Baum, L. G., Bakkers, J., Mayo, K. H., Poirier, F., and Griffioen, A. W. (2006) Gal-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc. Natl. Acad. Sci. U.S.A. 103, 15975-80.
11. Camby, I., Le Mercier, M., Lefranc, F., and Kiss, R. (2006) Gal-1: a small protein with major functions. Glycobiology. 16, 137R-157R.
12. Rabinovich, G. A. (2005) Gal-1 as a potential cancer target. Br. J. Cancer 92, 1188-92.
13. Gabius, H. J., Brehler, R., Schauer, A., and Cramer, F. (1986) Localization of endogenous lectins in normal human breast, benign breast lesions and mammary carcinomas. Virchows Arch. B. Cell. Pathol. Incl. Mol. Pathol. 52, 107-15.
14. Lotan, R., Matsushita, Y., Ohannesian, D., Carralero, D., Ota, D. M., Cleary, K. R., Nicolson, G. L., and Irimura, T. (1991) Lactose-binding lectin expression in human colorectal carcinomas. Relation to tumor progression. Carbohydr. Res. 213, 47-57.
15. Clausse, N., van den Brule, F., Waltregny, D., Garnier, F., and Castronovo, V. (1999) Gal-1 expression in prostate tumor-associated capillary endothelial cells is increased by prostate carcinoma cells and modulates heterotypic cell-cell adhesion. Angiogenesis 3, 317-25.
16. Allen, H. J., Sucato, D., Woynarowska, B., Gottstine, S., Sharma, A., and Bernacki, R. J. (1990) Role of galaptin in ovarian carcinoma adhesion to extracellular matrix in vitro. J. Cell. Biochem. 43, 43-57.
17. Akerman, M. E., Pilch, J., Peters, D., and Ruoslahti, E. (2005) Angiostatic peptides use plasma fibronectin to home to angiogenic vasculature. Proc. Natl. Acad. Sci. U.S.A. 102, 2040-5.
18. Dings, R. P., van der Schaft, D. W., Hargittai, B., Haseman, J., Griffioen, A. W., and Mayo, K. H. (2003) Anti-tumor activity of the novel angiogenesis inhibitor anginex. Cancer Lett. 194, 55-66.
19. Baekelandt, M. (2002) Irofulven (MGI Pharma). Curr. Opin. Invest. Drugs 3, 1517-26.
20. Eckhardt, S. G., Baker, S. D., Britten, C. D., Hidalgo, M., Siu, L., Hammond, L. A., Villalona-Calero, M. A., Felton, S., Drengler, R., Kuhn, J. G., Clark, G. M., Smith, S. L., MacDonald, J. R., Smith, C., Moczygemba, J., Weitman, S., Von Hoff, D. D., and Rowinsky, E. K. (2000) Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies. J. Clin. Oncol. 18, 4086-97.
21. Alexandre, J., Raymond, E., Kaci, M. O., Brain, E. C., Lokiec, F., Kahatt, C., Faivre, S., Yovine, A., Goldwasser, F., Smith, S. L., MacDonald, J. R., Misset, J. L., and Cvitkovic, E. (2004) Phase I and pharmacokinetic study of irofulven administered weekly or biweekly in advanced solid tumor patients. Clin. Cancer Res. 10, 3377-85.
22. Dings, R. P., Williams, B. W., Song, C. W., Griffioen, A. W., Mayo, K. H., and Griffin, R. J. (2005) Anginex synergizes with radiation therapy to inhibit tumor growth by radiosensitizing endothelial cells. Int. J. Cancer 115, 312-9.
23. Dings, R. P., Chen, X., Hellebrekers, D. M., van Eijk, L. I., Zhang, Y., Hoye, T. R., Griffioen, A. W., and Mayo, K. H. (2006) Design of nonpeptidic topomimetics of antiangiogenic proteins with antitumor activities. J. Natl. Cancer Inst. 98, 932-6.
24. Dings, R. P., Loren, M., Heun, H., McNiel, E., Griffioen, A. W., Mayo, K. H., and Griffin, R. J. (2007) Scheduling of radiation with angiogenesis inhibitors Anginex and Avastin improves therapeutic outcome via vessel normalization. Clin. Cancer Res. 13, 3395-402.
25. Mayo, K. H., Dings, R. P., Flader, C., Nesmelova, I., Hargittai, B., van der Schaft, D. W., van Eijk, L. I., Walek, D., Haseman, J., Hoye, T. R., and Griffioen, A. W. (2003) Design of a partial peptide mimetic of anginex with antiangiogenic and anticancer activity. J. Biol. Chem. 278, 45746-52.
26. Kadoya, T., and Horie, H. (2005) Structural and functional studies of gal-1: a novel axonal regeneration-promoting activity for oxidized gal-1. Curr. Drug Targets 6, 375-83.
27. Dings, R. P., Van Laar, E. S., Webber, J., Zhang, Y., Griffin, R. J., Waters, S. J., MacDonald, J. R., and Mayo, K. H. (2008) Ovarian tumor growth regression using a combination of vascular targeting agents anginex or topomimetic 0118 and the chemotherapeutic irofulven. Cancer Lett. 265, 270-80.
28. Wang, J., Wiltshire, T., Wang, Y., Mikell, C., Burks, J., Cunningham, C., Van Laar, E. S., Waters, S. J., Reed, E., and Wang, W. (2004) ATM-dependent CHK2 activation induced by anticancer agent, irofulven. J. Biol. Chem. 279, 39584-92.
29. Tattersall, M. H. N. (2002) Ovarian cancer chemotherapy: carboplatin as standard. The Lancet 360, 500-1.
30. Lee, T. Y., Tjin Tham Sjin, R. M., Movahedi, S., Ahmed, B., Pravda, E. A., Lo, K. M., Gillies, S. D., Folkman, J., and Javaherian, K. (2008) Linking antibody Fc domain to endostatin significantly improves endostatin half-life and efficacy. Clin. Cancer Res. 14, 1487-93.